Cargando…
Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy
PURPOSE: To investigate added morbidity associated with the addition of pelvic elective nodal irradiation (ENI) to hypofractionated radiotherapy to the prostate. METHODS AND MATERIALS: Two-hundred twelve patients, treated with hypofractionated radiotherapy to the prostate between 2004 and 2011, met...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060093/ https://www.ncbi.nlm.nih.gov/pubmed/24893842 http://dx.doi.org/10.1186/1748-717X-9-129 |
_version_ | 1782321323001774080 |
---|---|
author | McDonald, Andrew M Baker, Christopher B Popple, Richard A Shekar, Kiran Yang, Eddy S Jacob, Rojymon Cardan, Rex Kim, Robert Y Fiveash, John B |
author_facet | McDonald, Andrew M Baker, Christopher B Popple, Richard A Shekar, Kiran Yang, Eddy S Jacob, Rojymon Cardan, Rex Kim, Robert Y Fiveash, John B |
author_sort | McDonald, Andrew M |
collection | PubMed |
description | PURPOSE: To investigate added morbidity associated with the addition of pelvic elective nodal irradiation (ENI) to hypofractionated radiotherapy to the prostate. METHODS AND MATERIALS: Two-hundred twelve patients, treated with hypofractionated radiotherapy to the prostate between 2004 and 2011, met the inclusion criteria for the analysis. All patients received 70 Gy to the prostate delivered over 28 fractions and 103 (49%) received ENI consisting of 50.4 Gy to the pelvic lymphatics delivered simultaneously in 1.8 Gy fractions. The mean dose-volume histograms were compared between the two subgroups defined by use of ENI, and various dose-volume parameters were analyzed for effect on late lower gastrointestinal (GI) and genitourinary (GU) toxicity. RESULTS: Acute grade 2 lower GI toxicity occurred in 38 (37%) patients receiving ENI versus 19 (17%) in those who did not (p = 0.001). The Kaplan-Meier estimate of grade ≥ 2 lower GI toxicity at 3 years was 15.3% for patients receiving ENI versus 5.3% for those who did not (p = 0.026). Each rectal isodose volume was increased for patients receiving ENI up to 50 Gy (p ≤ 0.021 for each 5 Gy increment). Across all patients, the absolute V(70) of the rectum was the only predictor of late GI toxicity. When subgroups, defined by the use of ENI, were analyzed separately, rectal V(70) was only predictive of late GI toxicity for patients who received ENI. For patients receiving ENI, V(70) > 3 cc was associated with an increased risk of late GI events. CONCLUSIONS: Elective nodal irradiation increases the rates of acute and late GI toxicity when delivered simultaneously with hypofractioanted prostate radiotherapy. The use of ENI appears to sensitize the rectum to hot spots, therefore we recommend added caution to minimize the volume of rectum receiving 100% of the prescription dose in these patients. |
format | Online Article Text |
id | pubmed-4060093 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40600932014-06-18 Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy McDonald, Andrew M Baker, Christopher B Popple, Richard A Shekar, Kiran Yang, Eddy S Jacob, Rojymon Cardan, Rex Kim, Robert Y Fiveash, John B Radiat Oncol Research PURPOSE: To investigate added morbidity associated with the addition of pelvic elective nodal irradiation (ENI) to hypofractionated radiotherapy to the prostate. METHODS AND MATERIALS: Two-hundred twelve patients, treated with hypofractionated radiotherapy to the prostate between 2004 and 2011, met the inclusion criteria for the analysis. All patients received 70 Gy to the prostate delivered over 28 fractions and 103 (49%) received ENI consisting of 50.4 Gy to the pelvic lymphatics delivered simultaneously in 1.8 Gy fractions. The mean dose-volume histograms were compared between the two subgroups defined by use of ENI, and various dose-volume parameters were analyzed for effect on late lower gastrointestinal (GI) and genitourinary (GU) toxicity. RESULTS: Acute grade 2 lower GI toxicity occurred in 38 (37%) patients receiving ENI versus 19 (17%) in those who did not (p = 0.001). The Kaplan-Meier estimate of grade ≥ 2 lower GI toxicity at 3 years was 15.3% for patients receiving ENI versus 5.3% for those who did not (p = 0.026). Each rectal isodose volume was increased for patients receiving ENI up to 50 Gy (p ≤ 0.021 for each 5 Gy increment). Across all patients, the absolute V(70) of the rectum was the only predictor of late GI toxicity. When subgroups, defined by the use of ENI, were analyzed separately, rectal V(70) was only predictive of late GI toxicity for patients who received ENI. For patients receiving ENI, V(70) > 3 cc was associated with an increased risk of late GI events. CONCLUSIONS: Elective nodal irradiation increases the rates of acute and late GI toxicity when delivered simultaneously with hypofractioanted prostate radiotherapy. The use of ENI appears to sensitize the rectum to hot spots, therefore we recommend added caution to minimize the volume of rectum receiving 100% of the prescription dose in these patients. BioMed Central 2014-06-03 /pmc/articles/PMC4060093/ /pubmed/24893842 http://dx.doi.org/10.1186/1748-717X-9-129 Text en Copyright © 2014 McDonald et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research McDonald, Andrew M Baker, Christopher B Popple, Richard A Shekar, Kiran Yang, Eddy S Jacob, Rojymon Cardan, Rex Kim, Robert Y Fiveash, John B Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy |
title | Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy |
title_full | Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy |
title_fullStr | Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy |
title_full_unstemmed | Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy |
title_short | Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy |
title_sort | different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060093/ https://www.ncbi.nlm.nih.gov/pubmed/24893842 http://dx.doi.org/10.1186/1748-717X-9-129 |
work_keys_str_mv | AT mcdonaldandrewm differentrectaltoxicitytolerancewithandwithoutsimultaneousconventionallyfractionatedpelviclymphnodetreatmentinpatientsreceivinghypofractionatedprostateradiotherapy AT bakerchristopherb differentrectaltoxicitytolerancewithandwithoutsimultaneousconventionallyfractionatedpelviclymphnodetreatmentinpatientsreceivinghypofractionatedprostateradiotherapy AT popplericharda differentrectaltoxicitytolerancewithandwithoutsimultaneousconventionallyfractionatedpelviclymphnodetreatmentinpatientsreceivinghypofractionatedprostateradiotherapy AT shekarkiran differentrectaltoxicitytolerancewithandwithoutsimultaneousconventionallyfractionatedpelviclymphnodetreatmentinpatientsreceivinghypofractionatedprostateradiotherapy AT yangeddys differentrectaltoxicitytolerancewithandwithoutsimultaneousconventionallyfractionatedpelviclymphnodetreatmentinpatientsreceivinghypofractionatedprostateradiotherapy AT jacobrojymon differentrectaltoxicitytolerancewithandwithoutsimultaneousconventionallyfractionatedpelviclymphnodetreatmentinpatientsreceivinghypofractionatedprostateradiotherapy AT cardanrex differentrectaltoxicitytolerancewithandwithoutsimultaneousconventionallyfractionatedpelviclymphnodetreatmentinpatientsreceivinghypofractionatedprostateradiotherapy AT kimroberty differentrectaltoxicitytolerancewithandwithoutsimultaneousconventionallyfractionatedpelviclymphnodetreatmentinpatientsreceivinghypofractionatedprostateradiotherapy AT fiveashjohnb differentrectaltoxicitytolerancewithandwithoutsimultaneousconventionallyfractionatedpelviclymphnodetreatmentinpatientsreceivinghypofractionatedprostateradiotherapy |